GGrantIndex
Sort

51,593 grants matching hepatitis

Project 2: Molecular Signatures of West Nile virus susceptibility

$1,149,216
Ruth R Montgomery · Yale University · U19 · FY2021 · AI

DEMYELINATION DISEASE--VIRAL AND IMMUNE FUNCTION

$1,149,091
University Of Southern California · P01 · FY2000 · NS

The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction

$1,148,831
Sandra Ann Springer · Yale University · R01 · FY2019 · DA

The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction

$1,148,831
Sandra Ann Springer · Yale University · R01 · FY2017 · DA

The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction

$1,148,831
Sandra Ann Springer · Yale University · R01 · FY2020 · DA

Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing (S-ITEST)

$1,148,574
Juliet Iwelunmor · Washington University · UG1 · FY2024 · HD

SILVIO O.CONTE DIGESTIVE DISEASES RESEARCH CORE CENTERS

$1,148,390
James Lorenzen Boyer · Yale University · P30 · FY2008 · DK

SILVIO O.CONTE DIGESTIVE DISEASES RESEARCH CORE CENTERS

$1,148,390
James Lorenzen Boyer · Yale University · P30 · FY2007 · DK

MPS Qualification Section

$1,148,044
Mark E Schurdak · University Of Pittsburgh At Pittsburgh · U2C · FY2024 · TR

Biomarkers in Cancer Diagnosis, Prognosis and Therapeutic Outcome

$1,147,757
Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models

$1,147,252
Ashley Brown · University Of Florida · R01 · FY2014 · AI

Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

$1,146,607
Walter Powell · Starks Associates, Inc. · N01 · FY2013 · AI

Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care

$1,146,565
Bruce R Schackman · Weill Medical Coll Of Cornell Univ · P30 · FY2019 · DA

Endocannabinoids And Energy Homeostasis

$1,146,334
George Kunos · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2022 · AA

Molecular signatures for liver cancer diagnosis and treatment stratification

$1,145,964
Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings

$1,144,825
Frederick Lewis Altice · Yale University · R01 · FY2025 · DA

ZCM: A novel broad-spectrum microbicide for STIs

$1,144,510
Melissa J Robbiani · Population Council · U19 · FY2006 · AI

Role of Oral vs Injectable Glucagon Suppressors

$1,144,210
Rubina A Heptulla · Albert Einstein College Of Medicine · DP3 · FY2013 · DK

Integrating HCV services into HIV programs for PWID in India

$1,144,204
Shruti H Mehta · Johns Hopkins University · R01 · FY2021 · AI

PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis

$1,143,959
Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2024 · AI

USC Research Center for Liver Disease

$1,143,582
Neil Kaplowitz · University Of Southern California · P30 · FY2018 · DK

Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets

$1,143,103
D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UG3 · FY2019 · DK

Metabolic Studies of Mouse Models of Obesity and Diabetes

$1,142,985
Oksana Gavrilova · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIC · FY2024 · DK

Structure-Based Vaccine Design for Hepatits C Virus

$1,142,860
Thomas R Fuerst · Univ Of Maryland, College Park · R01 · FY2018 · AI

Cornell Clinical Trials Unit

$1,142,381
Roy M Gulick · Weill Medical Coll Of Cornell Univ · U01 · FY2007 · AI